Objective： To observe the effect of Chinese medicine Shenshao Tablet （参芍片, SST） on the quality of life in coronary heart disease （CHD） patients with stable angina pectoris （SAP）. Methods： Sixty-six patients...Objective： To observe the effect of Chinese medicine Shenshao Tablet （参芍片, SST） on the quality of life in coronary heart disease （CHD） patients with stable angina pectoris （SAP）. Methods： Sixty-six patients with SAP confirmed by coronary angiography were enrolled and assigned to two groups by means of PROC PLAN using a SAS 6.12 software in a double-blinded, randomized, placebo-controlled design. Patients in the treated group were treated with SST, and the others in the control group were given placebo. The weekly angina frequency, quality of life scale [Seattle Angina Questionnaire （SAQ）] and incidence of important clinical events were observed to evaluate the intervention effect of SST on the quality of life for CHD patients with SAP. Results： During the study, one case dropped out in the treated group and two cases in the control group, respectively, and 63 cases including 32 cases in the treated group, and 31 cases in the control group completed the trial. After four weeks of treatment, the weekly angina frequency of the treated group （5.32± 2.46 times per week） was significantly less than that of the control group （7.32± 3.20 times per week, P 〈 0.05）. The total score of the quality of life in the treated group （71.30± 5.44） was obviously higher than that in the control group （63.50± 4.60, P 〈 0.01）, and the angina stability, angina frequency, and treatment satisfaction were significantly superior to those in the control group （P〈 0.01）. The incidence of important clinical events of the treated group （3.1%） was lower than that of the control group （6.5%） during the six-month follow-up period, but the difference was insignificant （P 〉 0.05）. Conclusion： SST could lower the angina frequency and greatly improve the quality of life in CHD patients with SAP.展开更多
Objective： To observe the effect of Yiqi Yangyin Decoction （益气养阴方, YQYYD） on the quality of life （QOL） of patients with unstable angina pectoris （UAP）. Methods： A total of 108 patients with UAP of qi-yin ...Objective： To observe the effect of Yiqi Yangyin Decoction （益气养阴方, YQYYD） on the quality of life （QOL） of patients with unstable angina pectoris （UAP）. Methods： A total of 108 patients with UAP of qi-yin deficiency syndrome confirmed by coronary angiography were enrolled and assigned to the treated group （treated with YQYYD and conventional therapy of Western medicine） and the control group （treated with conventional therapy of Western medicine）, by the use of the PROC PLAN of the SAS 6.12 software, in a prospective, randomized, controlled design. The clinical total effective rate, symptom score, QOL scale [Seattle Angina Questionnaire （SAQ）] and incidence of important clinical events were defined as the observation indices to evaluate the interventional effect of YQYYD on the QOL of patients with UAP of the qi-yin deficiency syndrome. Results： During the study, three cases dropped out in the treated group, one case dropped out in the control group, and 104 cases, including 51 cases in the treatment group and 53 cases in the control group, finished the trial. After four weeks of treatment, the total clinical effective rates in the treated group and the control group were 80.4% and 75.5% respectively, and there was no obvious difference between them （P〉0.05）. However, the symptom score of the treated group （9.31 ± 2.02） was significantly lesser than that of the control group （11.62 ± 3.04, P〈0.05）, and the total score of the QOI scale of the treated group （68.76 ± 5.74） was significantly higher than that of the control group （61.06 ±3.31, P〈0.01）. Among those in the treated group physical limitation, angina stability, angina frequency, and treatment satisfaction were significantly ameliorated when compared with the control group after treatment （P〈0.05, P〈0.01）. The incidence of important clinical events in the treated group （3.9%） was lower than that in the control group （5.7%） during the 8-month follow-up period, but the difference was insignificant （P〉0.05）. Conclusion： YQYYD could improve the clinical symptoms of patients with UAP of qi-yin deficiency syndrome and greatly improve their QOL.展开更多
基金Supported by the Major State Basic Research Development Program of China(973 Program,No.2003CB517103)the National Medical Science and Technique Foundation during the 10th Five-Year Plan Period(No.2004BA721A01HO9)the National Natural Science Foundation of China(No.90209011)
文摘Objective： To observe the effect of Chinese medicine Shenshao Tablet （参芍片, SST） on the quality of life in coronary heart disease （CHD） patients with stable angina pectoris （SAP）. Methods： Sixty-six patients with SAP confirmed by coronary angiography were enrolled and assigned to two groups by means of PROC PLAN using a SAS 6.12 software in a double-blinded, randomized, placebo-controlled design. Patients in the treated group were treated with SST, and the others in the control group were given placebo. The weekly angina frequency, quality of life scale [Seattle Angina Questionnaire （SAQ）] and incidence of important clinical events were observed to evaluate the intervention effect of SST on the quality of life for CHD patients with SAP. Results： During the study, one case dropped out in the treated group and two cases in the control group, respectively, and 63 cases including 32 cases in the treated group, and 31 cases in the control group completed the trial. After four weeks of treatment, the weekly angina frequency of the treated group （5.32± 2.46 times per week） was significantly less than that of the control group （7.32± 3.20 times per week, P 〈 0.05）. The total score of the quality of life in the treated group （71.30± 5.44） was obviously higher than that in the control group （63.50± 4.60, P 〈 0.01）, and the angina stability, angina frequency, and treatment satisfaction were significantly superior to those in the control group （P〈 0.01）. The incidence of important clinical events of the treated group （3.1%） was lower than that of the control group （6.5%） during the six-month follow-up period, but the difference was insignificant （P 〉 0.05）. Conclusion： SST could lower the angina frequency and greatly improve the quality of life in CHD patients with SAP.
基金Supported by the National Basic Research Program of China (973 Program,No.2003CB517103)the Traditional Chinese Medicine-treated Characteristic and Dominant Diseases Program of China Academy of Chinese Medical Sciences(No. CACMS05Y0010)
文摘Objective： To observe the effect of Yiqi Yangyin Decoction （益气养阴方, YQYYD） on the quality of life （QOL） of patients with unstable angina pectoris （UAP）. Methods： A total of 108 patients with UAP of qi-yin deficiency syndrome confirmed by coronary angiography were enrolled and assigned to the treated group （treated with YQYYD and conventional therapy of Western medicine） and the control group （treated with conventional therapy of Western medicine）, by the use of the PROC PLAN of the SAS 6.12 software, in a prospective, randomized, controlled design. The clinical total effective rate, symptom score, QOL scale [Seattle Angina Questionnaire （SAQ）] and incidence of important clinical events were defined as the observation indices to evaluate the interventional effect of YQYYD on the QOL of patients with UAP of the qi-yin deficiency syndrome. Results： During the study, three cases dropped out in the treated group, one case dropped out in the control group, and 104 cases, including 51 cases in the treatment group and 53 cases in the control group, finished the trial. After four weeks of treatment, the total clinical effective rates in the treated group and the control group were 80.4% and 75.5% respectively, and there was no obvious difference between them （P〉0.05）. However, the symptom score of the treated group （9.31 ± 2.02） was significantly lesser than that of the control group （11.62 ± 3.04, P〈0.05）, and the total score of the QOI scale of the treated group （68.76 ± 5.74） was significantly higher than that of the control group （61.06 ±3.31, P〈0.01）. Among those in the treated group physical limitation, angina stability, angina frequency, and treatment satisfaction were significantly ameliorated when compared with the control group after treatment （P〈0.05, P〈0.01）. The incidence of important clinical events in the treated group （3.9%） was lower than that in the control group （5.7%） during the 8-month follow-up period, but the difference was insignificant （P〉0.05）. Conclusion： YQYYD could improve the clinical symptoms of patients with UAP of qi-yin deficiency syndrome and greatly improve their QOL.
